2675 Stock Overview
Engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.18 |
| 52 Week High | CN¥20.15 |
| 52 Week Low | CN¥12.05 |
| Beta | 0.32 |
| 1 Month Change | -1.13% |
| 3 Month Change | -16.79% |
| 1 Year Change | -7.18% |
| 3 Year Change | -34.85% |
| 5 Year Change | 15.92% |
| Change since IPO | -14.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2675 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -5.0% | -0.03% | 0.06% |
| 1Y | -7.2% | -20.2% | -16.1% |
Return vs Industry: 002675 exceeded the CN Biotechs industry which returned -20.2% over the past year.
Return vs Market: 002675 exceeded the CN Market which returned -16.1% over the past year.
Price Volatility
| 2675 volatility | |
|---|---|
| 2675 Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 10.2% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 002675 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002675's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 2,333 | Zhi Gang Luo | www.dcb-group.com |
Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas. It offers heparin, chondroitin sulphate sodium and calcium, and glucosamine series products, as well as collagen, hyaluronic acid, and cytochrome C. The company also provides nadroparin calcium, hydrocortisone sodium succinate, chorionic gonadotrophin, and menotropins for injection, as well as ambroxol hydrochloride dispersible tablets, jinjunling capsule, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind dispelling itch relieving granule. In addition, it offers Technetium [99Tc] Methylene Diphosphonate Injection; Technetium [99mTc] Tc labeled tracers; 2-[18F]FDG that helps to detect the activity of tumor cells; sodium iodide [131I] oral solution; iodine [125I] seed use to treat internal radiation of various malignant tumors; [14C]Urea capsule; and jiabaolin glucosamine chondroitin sulfate capsule.
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Fundamentals Summary
| 2675 fundamental statistics | |
|---|---|
| Market cap | CN¥10.87b |
| Earnings (TTM) | CN¥223.96m |
| Revenue (TTM) | CN¥3.07b |
48.5x
P/E Ratio3.5x
P/S RatioIs 2675 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2675 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.07b |
| Cost of Revenue | CN¥1.84b |
| Gross Profit | CN¥1.23b |
| Other Expenses | CN¥1.01b |
| Earnings | CN¥223.96m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.27 |
| Gross Margin | 40.17% |
| Net Profit Margin | 7.29% |
| Debt/Equity Ratio | 15.9% |
How did 2675 perform over the long term?
See historical performance and comparison